Clozapine use in children and adolescents

Bibliography

• Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-96
   PubMed Web of Science ®Google Scholar
• Hafner H, Nowotny B. Epidemiology of early-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 1995;245(2):80-92
   PubMed Web of Science ®Google Scholar
• Krausz M, Muller-Thomsen T. Schizophrenia with onset in adolescence: an 11-year followup. Schizophr Bull 1993;19(4):831-41
   PubMed Web of Science ®Google Scholar
• Nicolson R, Rapoport JL. Childhood-onset schizophrenia: rare but worth studying. Biol Psychiatry 1999;46(10):1418-28
   PubMed Web of Science ®Google Scholar
• Childs B, Scriver CR. Age at onset and causes of disease. Perspect Biol Med 1986;29(3 Pt 1):437-60
   PubMed Web of Science ®Google Scholar
• Luft B, Taylor D. A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opin Pharmacother 2006;7(13):1739-48
   PubMed Web of Science ®Google Scholar
• Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry Suppl 1992;17:41-5
   Google Scholar
• McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163(4):600-10
   PubMed Web of Science ®Google Scholar
• Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63(10):1079-87
   PubMed Web of Science ®Google Scholar
• Davies LM, Jones PB, Barnes TR, et al. Cost-effectiveness of first-v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 2007;191:14-22
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
   PubMed Web of Science ®Google Scholar
• Nasrallah HA. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. J Clin Psychiatry 2007;68(Suppl 1):5-11
   PubMedGoogle Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60(6):553-64
   PubMed Web of Science ®Google Scholar
• Woerner MG, Robinson DG, Alvir JMJ, et al. Clozapine as a first treatment for schizophrenia. Am J Psychiatry 2003;160(8):1514-6
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003;28(5):995-1003
   PubMed Web of Science ®Google Scholar
• Agid O, Remington G, Kapur S, et al. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol 2007;27(4):369-73
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156(2):286-93
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001;158(3):360-9
   PubMed Web of Science ®Google Scholar
• Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006;20(5):389-409
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Gardner DM, Garver DL. Conversions from clozapine to other antipsychotic drugs. Arch Gen Psychiatry 1995;52(12):1071-2
   PubMed Web of Science ®Google Scholar
• Garver DL. Evolution of antipsychotic intervention in the schizophrenic psychosis. Curr Drug Targets 2006;7(9):1205-15
   PubMed Web of Science ®Google Scholar
• Rapoport JL, Gogtay N. Brain neuroplasticity in healthy, hyperactive and psychotic children: insights from neuroimaging. Neuropsychopharmacology 2008;33(1):181-97
   PubMed Web of Science ®Google Scholar
• Green SM, Sherwin TS. Incidence and severity of recovery agitation after ketamine sedation in young adults. Am J Emerg Med 2005;23(2):142-4
   PubMed Web of Science ®Google Scholar
• Farber NB, Newcomer JW, Olney JW. The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. Prog Brain Res 1998;116:421-37
   PubMed Web of Science ®Google Scholar
• Thompson PM, Vidal C, Giedd JN, et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci USA 2001;98(20):11650-5
   PubMed Web of Science ®Google Scholar
• Towbin KE, Dykens EM, Pugliese RG. Clozapine for early developmental delays with childhood-onset schizophrenia: protocol and 15-month outcome. J Am Acad Child Adolesc Psychiatry 1994;33(5):651-7
   PubMed Web of Science ®Google Scholar
• Mozes T, Toren P, Chernauzan N, et al. Clozapine treatment in very early onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1994;33(1):65-70
   PubMed Web of Science ®Google Scholar
• Remschmidt H, Hennighausen H, Clement HW, et al. Atypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 2000;9(Suppl 1):I9-19
   Web of Science ®Google Scholar
• Remschmidt H, Fleischhaker C, Hennighausen K, Schulz E. Management of schizophrenia in children and adolescents. The role of clozapine. Paediatr Drugs 2000;2(4):253-62
   PubMedGoogle Scholar
• Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53(12):1090-7
   PubMed Web of Science ®Google Scholar
• Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006;63(7):721-30
   PubMed Web of Science ®Google Scholar
• Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 2007
   PubMedGoogle Scholar
• Teicher M, Barbar N, Gelbard H, et al. Developmental differences in acute nigrostriatal and mesocorticolimbic system response to haloperidol. Neuropsychopharmacology 1993;9(2):147-56
   PubMed Web of Science ®Google Scholar
• Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry 1998;43(6):596-604
   PubMed Web of Science ®Google Scholar
• Kranzler HN, Kester HM, Gerbino-Rosen G, et al. Treatment-refractory schizophrenia in children and adolescents: an update on clozapine and other pharmacologic interventions. Child Adolesc Psychiatr Clin N Am 2006;15(1):135-59
   PubMed Web of Science ®Google Scholar
• Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329(3):162-7
   PubMed Web of Science ®Google Scholar
• Kennedy E, Kumar A, Datta S. Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database Syst Rev 2007;3:CD004027
   Google Scholar
• Gerbino-Rosen G, Roofeh D, Tompkins DA, et al. Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry 2005;44(10):1024-31
   PubMed Web of Science ®Google Scholar
• Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991;148(2):231-5
   PubMed Web of Science ®Google Scholar
• Miller DD, Fleming F, Holman TL, Perry PJ. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994;55(Suppl B):117-21
   PubMed Web of Science ®Google Scholar
• Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994;55(Suppl B):133-6
   PubMed Web of Science ®Google Scholar
• Kronig MH, Munne RA, Szymanski S, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995;152(2):179-82
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Frazier JA, McKenna K, et al. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. J Clin Psychiatry 1994;55(Suppl B):94-7
   PubMed Web of Science ®Google Scholar
• Sporn AL, Vermani A, Greenstein DK, et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 2007;46(10):1349-56
   PubMed Web of Science ®Google Scholar
• Andreasen NC. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006;113(2):81
   PubMed Web of Science ®Google Scholar
• Martin RL, Cloninger CR, Guse SB. Frequency and differential diagnosis of depressive syndromes in schizophrenia. J Clin Psychiatry 1985;46(11 Pt 2):9-13
   PubMed Web of Science ®Google Scholar
• Braga RJ, Mendlowicz MV, Marrocos RP, Figueira IL. Anxiety disorders in outpatients with schizophrenia: prevalence and impact on the subjective quality of life. J Psychiatr Res 2005;39(4):409-14
   PubMed Web of Science ®Google Scholar
• Pallanti S, Quercioli L, Hollander E. Social anxiety in outpatients with schizophrenia: a relevant cause of disability. Am J Psychiatry 2004;161(1):53-8
   PubMed Web of Science ®Google Scholar
• Tossell JW, Greenstein DK, Davidson AL, et al. Stimulant drug treatment in childhood-onset schizophrenia with comorbid ADHD: an open-label case series. J Child Adolesc Psychopharmacol 2004;14(3):448-54
   PubMed Web of Science ®Google Scholar
• Sporn A, Gogtay N, Oritz AR, et al. Clozapine-induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol 2003;13(3):401-4
   PubMed Web of Science ®Google Scholar
• Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007;62(4):345-54
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Shelton MD , Baker RW, et al. The prevalence of akathisia in patients receiving stable doses of clozapine. J Clin Psychiatry 1994;55(4):142-5
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Shelton MD, Baker RW, et al. Clozapine-induced akathisia in children with schizophrenia. J Child Adolesc Psychopharmacol 2002;12(4):347-9
   PubMed Web of Science ®Google Scholar
• Wudarsky M, Nicolson R, Hamburger SD, et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 1999;9(4):239-45
   PubMed Web of Science ®Google Scholar
• Baptista T, Hernandez L, Prieto LA, et al. Metformin in obesity associated with antipsychotic drug administration: a pilot study. J Clin Psychiatry 2001;62(8):653-5
   PubMed Web of Science ®Google Scholar
• Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002;159(4):655-7
   PubMed Web of Science ®Google Scholar
• Dervaux A, Cazali J. Clozapine and amisulpride in refractory schizophrenia and alcohol dependence. J Clin Psychopharmacol 2007;27(5):514-6
   PubMed Web of Science ®Google Scholar